Inspire Pharma shares soar 75% on CF data

Shares of Durham, NC-based Inspire Pharmaceuticals took off this morning after researchers announced that a late-stage trial of its cystic fibrosis therapy produced promising results. Patients taking the drug experienced an improvement in lung function during the 24-week study. After hearing the news on denufosol, investors pushed up Inspire's shares by more than 75 percent.

"The data from this Phase 3 trial with denufosol are encouraging for the cystic fibrosis community because it brings us one step closer to a novel treatment that addresses the basic cystic fibrosis defect," Robert J. Beall, CEO of the Cystic Fibrosis Foundation.

- read the report in the Triangle Business Journal

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.